FDA Drug Review Head Is Jenkins, Ending 15-Month Search
This article was originally published in The Tan Sheet
Executive Summary
Office of Drug Evaluation II Director John Jenkins, MD, will take over as FDA's top drug review manager effective Jan. 2. The agency announced the appointment of Jenkins as Office of Review Management director in a staff memo Dec. 11
You may also be interested in...
FDA staffing
Sandra Kweder, MD, named ODE II acting director effective Jan. 13, filling post vacated by John Jenkins, MD, who is now Office of New Drugs director. Jenkins, Kweder essentially swapped roles, as Kweder was former acting director of Office of Review Management, now known as OND (1"The Tan Sheet" Dec. 17, 2001, p. 9)...
FDA staffing
Sandra Kweder, MD, named ODE II acting director effective Jan. 13, filling post vacated by John Jenkins, MD, who is now Office of New Drugs director. Jenkins, Kweder essentially swapped roles, as Kweder was former acting director of Office of Review Management, now known as OND (1"The Tan Sheet" Dec. 17, 2001, p. 9)...
FDA staffing
Sandra Kweder, MD, named ODE II acting director effective Jan. 13, filling post vacated by John Jenkins, MD, who is now Office of New Drugs director. Jenkins, Kweder essentially swapped roles, as Kweder was former acting director of Office of Review Management, now known as OND (1"The Tan Sheet" Dec. 17, 2001, p. 9)...